<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356940</url>
  </required_header>
  <id_info>
    <org_study_id>A randomized</org_study_id>
    <nct_id>NCT01356940</nct_id>
  </id_info>
  <brief_title>A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis</brief_title>
  <official_title>A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown, Theodore R., M.D., MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown, Theodore R., M.D., MPH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect
      on ambulatory activity in people with multiple sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel-group, double-blind, randomized controlled crossover trial with a 1:1
      randomization. There are two treatment periods of 4 weeks and a two-week off treatment
      washout period. Treatment periods are DER (dalfampridine ER) followed by placebo (group A)
      and placebo followed by DER (group B), respectively. All dosages will be administered twice a
      week. Purpose of the study is to see if using the study drug(dalfampridine Er) for a short
      period of time will improve the way subjects with multiple sclerosis (MS) walk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Activity Index</measure>
    <time_frame>10 weeks</time_frame>
    <description>peak activity index is a measure of the 30 fastest minutes of walking over a 24 hour period, averaged over one week of accelerometer wear. Measurement is change from baseline to 4 weeks on intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stepcount</measure>
    <time_frame>10 weeks</time_frame>
    <description>daily stepcount recorded by an accelerometer and averaged over 1 week of wear</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>dalfampridine ER 10mg bid-placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-dalfampridine ER 10mg bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalfampridine ER</intervention_name>
    <description>dalfampridine ER 10mg bid for 4 weeks</description>
    <arm_group_label>dalfampridine ER 10mg bid-placebo</arm_group_label>
    <arm_group_label>placebo-dalfampridine ER 10mg bid</arm_group_label>
    <other_name>Ampyra serial number 77948545</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>identical placebo tablet administered bid for four weeks</description>
    <arm_group_label>dalfampridine ER 10mg bid-placebo</arm_group_label>
    <arm_group_label>placebo-dalfampridine ER 10mg bid</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MS made at least 3 months prior to based McDonald or Proser criteria.

          -  Age 18-75 years old inclusive.

          -  Expanded Disability Status Scale (EDS) 0-6.5

          -  Clinical stability defined as no MS exacerbation or change in disease modifying
             therapy for 60 days prior to screening.

          -  Screening 6-minute walking test distance between 50m-500m, inclusive.

          -  Written informed consent.

        Exclusion Criteria:

          -  use of 4-aminopyridine within 6 months of screening

          -  Any contraindication to DER:

               -  Allergy to DER

               -  history of seizure disorder or history of EEG showing epileptiform activity

               -  Renal insufficiency (estimated GFR &lt; 60.

          -  Any condition that would exclude 6 minute walking testing:

               -  Cardiac surgery or myocardial infarction within the last 3 months.

               -  Severe aortic stenosis or hypertropic cardiomyopathy.

               -  Pulmonary embolus or infarction in the last 6 months.

               -  Uncontrolled hypertension by history or by screening or baseline diastolic blood
                  pressure &gt; 170, or systolic blood pressure &gt; 105.

               -  Use of oxygen at home for 24 hours/day or severe lung disease.

          -  History of ventricular arrhythmia or finding of significant ventricular arrhythmia.
             atrial arrhythmia or 2nd or 3rd degree heart block on screening ECG.

          -  Concomitant neurological disease, such as ALS, Parkinson Disease, stroke.

          -  Hospitalization in the last 6 months for psychiatric illness.

          -  Alcohol or drug abuse within the past year.

          -  Females who are breast-feeding, pregnant or have potential to become pregnant during
             the course of the study( fertile and unwilling/unable to use effective contraceptive
             measures)

          -  Cognitive deficits that would interfere with the subject's ability to give informed
             consent or preform study testing.

          -  Any other serious and/or unstable medical condition.

          -  Use of mitoxantrone (Novantrone) within 6 months of baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore R Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EvergreenHealth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MS Center at Evergreen</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>April 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2015</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown, Theodore R., M.D., MPH</investigator_affiliation>
    <investigator_full_name>Theodore R Brown</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Ambulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalfampridine ER 10mg Bid- Placebo</title>
          <description>4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo-dalfampridine ER 10mg Bid</title>
          <description>placebo tablet administered bid for four weeks followed by 2 week washout and dalfampridine ER: dalfampridine ER 10mg bid for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dalfampridine ER 10mg Bid Followed by Placebo</title>
          <description>• Age 18-75 inclusive, Male or Female 4 week administration of dalfampridine ER 10mg bid
Group A: dalfampridine ER 10mg bid for 4 weeks, 2 week washout, then matching placebo for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by Dalfampridine ER 10mg Bid</title>
          <description>• Age 18-75 inclusive, Male or Female identical placebo tablet administered bid for four weeks
Group B: identical placebo tablet administered bid for four weeks, 2 week washout, then dalfampridine ER 10mg bid for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="2.5"/>
                    <measurement group_id="B2" value="53.3" spread="2.2"/>
                    <measurement group_id="B3" value="54.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>female patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>male patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Activity Index</title>
        <description>peak activity index is a measure of the 30 fastest minutes of walking over a 24 hour period, averaged over one week of accelerometer wear. Measurement is change from baseline to 4 weeks on intervention</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine ER 10mg Bid</title>
            <description>4 week administration of dalfampridine ER 10mg bid
dalfampridine ER: dalfampridine ER 10mg bid for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebo tablet administered bid for four weeks
placebo: identical placebo tablet administered bid for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Activity Index</title>
          <description>peak activity index is a measure of the 30 fastest minutes of walking over a 24 hour period, averaged over one week of accelerometer wear. Measurement is change from baseline to 4 weeks on intervention</description>
          <units>change in strides per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.54"/>
                    <measurement group_id="O2" value="0.3" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.586</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.586</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>P values above 0.05 are considered statistically not significant in this study</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stepcount</title>
        <description>daily stepcount recorded by an accelerometer and averaged over 1 week of wear</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalfampridine ER 10mg Bid</title>
          <description>4 week administration of dalfampridine ER 10mg bid
dalfampridine ER: dalfampridine ER 10mg bid for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>identical placebo tablet administered bid for four weeks
placebo: identical placebo tablet administered bid for four weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>worsening balance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore R. Brown, MD</name_or_title>
      <organization>MS Center at Evergreenhealth</organization>
      <phone>425-899-5350</phone>
      <email>trbrown@evergreenhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

